# A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

> **NCT06273553** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **RinuaGene Biotechnology Co., Ltd.** · enrollment: 39 (estimated)

## Conditions studied

- Human Papillomavirus Associated Intraepithelial Neoplasia
- Cervical Intraepithelial Neoplasia Grade 2/3
- Human Papillomavirus Type 16 Infection
- Human Papillomavirus Type 18 Infection

## Interventions

- **BIOLOGICAL:** RG002 injection

## Key facts

- **NCT ID:** NCT06273553
- **Lead sponsor:** RinuaGene Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03
- **Primary completion:** 2026-10
- **Final completion:** 2027-12
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06273553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06273553, "A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06273553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*